The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
    • Content Hubs
Subscribe
Subscribe
The Medicine Maker / Issues / 2026 / August / From Training Burden to Training Value 
Business & Regulation Development & Clinical Regulation & Standards Business & Trends Technology & Manufacturing Sponsored

From Training Burden to Training Value 

Why effective study training depends on relevance, timing, and oversight.

08/14/2026 0 min read Interview

Share

Study training is essential to clinical trial compliance, but assigning, tracking, and documenting it across global studies can consume time better spent improving training quality and impact. Reducing that burden helps ensure that each person receives the right training at the right time.

Tine De Pla of Amgen and Aidan Gannon of Veeva Systems discuss how role-based automation can strengthen oversight, reduce unnecessary training, and deliver more timely, useful learning. They also explore the links between effective training, patient safety, trial execution, and data quality.

Watch the interview.

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Recommended

Related Content

Musings from The Power List: Michael May
Cell & Gene Development & Clinical Interviews
Musings from The Power List: Michael May

September 22, 2026

5 min read

CCRM CEO Michael May on quantum computing, commercialization, and the next era of cell therapy

LongTerm Data Boost MCO010
Development & Clinical Cell & Gene Research News
Long-Term Data Boost MCO-010

September 21, 2026

2 min read

Four-year RESTORE results will shed new light on the durability of Nanoscope’s mutation-agnostic optogenetic therapy

Musings from The Power List: Dajun Yang
Small Molecules Development & Clinical Interviews
Musings from The Power List: Dajun Yang

September 15, 2026

4 min read

The Ascentage Pharma CEO on why next-generation small molecules are expanding into territory once reserved for biologics

Musings from The Power List: Ali Tavassoli
Small Molecules Drug Discovery Development & Clinical
Musings from The Power List: Ali Tavassoli

September 10, 2026

8 min read

Ali Tavassoli explains how cyclic peptides and new discovery tools are opening up once-inaccessible biology

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions: